Compare NVNO & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVNO | NCNA |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 13.8M |
| IPO Year | N/A | 2017 |
| Metric | NVNO | NCNA |
|---|---|---|
| Price | $0.36 | $3.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 417.4K | 60.7K |
| Earning Date | 02-27-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $2.78 |
| 52 Week High | $5.62 | $268.00 |
| Indicator | NVNO | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 48.56 |
| Support Level | $0.35 | $3.50 |
| Resistance Level | $0.39 | $3.77 |
| Average True Range (ATR) | 0.03 | 0.19 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 52.36 | 77.42 |
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.